Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge
复制标题
DOI：
10.1016/j.ejca.2017.07.002
复制
发表时间：
2017
影响因子：
8.4
通讯作者：
O'Brien Mary
中科院分区：
文献类型：
--
作者：
Su Chunxia;Zhou Fei;Shen Jiqiao;Zhao Jing;O'Brien Mary
